AAPL 241.54 1.9715% MSFT 408.54 -0.1222% NVDA 135.025 2.9625% GOOGL 184.08 0.256% GOOG 185.9503 0.2806% AMZN 228.68 -0.1092% META 722.78 -0.3584% AVGO 232.395 -1.6734% LLY 871.95 -0.1168% TSLA 351.1 4.3357% TSM 201.8233 -2.2079% V 353.5047 0.5732% JPM 274.89 -0.2033% UNH 529.15 0.3318% NVO 78.985 -3.4295% WMT 104.4714 0.8314% LVMUY 147.59 1.9831% XOM 108.06 0.6614% LVMHF 736.55 1.5371% MA 564.34 -0.0461%
Last update at 2025-02-13T18:58:00Z
Why Eli Lilly and Company (LLY) is the Best Long-Term Growth Stock to Buy Now
Wed 12 Feb 25, 01:56 PMWhy the 'best hedge' against the AI rally losing steam in 2025 is healthcare: Morning Brief
Wed 12 Feb 25, 11:00 AMEli Lilly and Company (LLY): A Bull Case Theory
Tue 11 Feb 25, 07:28 PMJim Cramer Backs Eli Lilly (LLY): Will Its Drug Pipeline Dominate Pharma?
Tue 11 Feb 25, 05:09 PMEli Lilly (LLY) Expands AdvanCell Partnership for Cutting-Edge Cancer Therapies
Mon 10 Feb 25, 11:01 PMPRIMECAP Management's Strategic Moves: A Closer Look at Eli Lilly and Co
Mon 10 Feb 25, 10:03 PMEli Lilly and Company (LLY): The Best Dividend Growth Stock With Over 10% Yearly Increases?
Mon 10 Feb 25, 06:35 PMEli Lilly Seeks To Expand Into Cancer Radiopharma And Fatty Liver, With Two Global Deals
Mon 10 Feb 25, 04:55 PMBreakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
---|---|---|---|---|---|
Type | yearly | yearly | yearly | yearly | yearly |
Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
Income before tax | 6806.40M | 6155.50M | 7229.90M | 5265.90M | 3680.10M |
Minority interest | - | - | 183.60M | 92.20M | 1080.40M |
Net income | 6244.80M | 5581.70M | 6193.70M | 4637.90M | 3232.00M |
Selling general administrative | 6440.40M | 6431.60M | 6121.20M | 6213.80M | 5975.10M |
Selling and marketing expenses | - | - | - | 6213.80M | 5975.10M |
Gross profit | 21911.60M | 21005.60M | 19056.50M | 17598.30M | 16811.60M |
Reconciled depreciation | 1522.50M | 1547.60M | 1323.90M | 1232.60M | 1609.00M |
Ebit | 7127.30M | 6357.10M | 6058.00M | 4974.30M | 8036.10M |
Ebitda | 9433.50M | 8739.10M | 7641.20M | 6604.70M | 9645.10M |
Depreciation and amortization | 2306.20M | 2382.00M | 1583.20M | 1630.40M | 1609.00M |
Non operating income net other | -320.90000M | - | - | 291.60M | 74.80M |
Operating income | 7127.30M | 6357.10M | 6058.00M | 4974.30M | 6186.80M |
Other operating expenses | 20261.00M | 20770.30M | 17690.20M | 16530.00M | 15708.00M |
Interest expense | 331.60M | 339.80M | 359.60M | 400.60M | 272.10M |
Tax provision | 561.60M | 573.80M | 1036.20M | 628.00M | 563.70M |
Interest income | 268.80M | 314.40M | 326.60M | 80.40M | 161.30M |
Net interest income | -268.80000M | -314.40000M | -326.60000M | -320.20000M | -110.80000M |
Extraordinary items | - | 0.00000M | 0.00000M | 3680.50M | -93.90000M |
Non recurring | 244.60M | - | - | 815.20M | 2465.90M |
Other items | - | - | - | - | - |
Income tax expense | 561.60M | 573.80M | 1036.20M | 628.00M | 529.50M |
Total revenue | 28541.40M | 28318.40M | 24539.80M | 22319.50M | 21493.30M |
Total operating expenses | 13631.20M | 13457.50M | 12206.90M | 11808.80M | 11026.30M |
Cost of revenue | 6629.80M | 7312.80M | 5483.30M | 4721.20M | 4681.70M |
Total other income expense net | -320.90000M | -201.60000M | 1171.90M | 291.60M | -2105.20000M |
Discontinued operations | - | - | - | 3680.50M | 81.40M |
Net income from continuing ops | 6244.80M | 5581.70M | 6193.70M | 4637.90M | 3232.00M |
Net income applicable to common shares | 6244.80M | 5581.70M | 6193.70M | 8318.40M | 3232.00M |
Preferred stock and other adjustments | - | - | - | - | - |
Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
---|---|---|---|---|---|
Type | yearly | yearly | yearly | yearly | yearly |
Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
Total assets | 64006.30M | 49489.80M | 48806.00M | 46633.10M | 39286.10M |
Intangible assets | 6906.60M | 7206.60M | 7691.90M | 7450.00M | 6618.00M |
Earning assets | - | - | - | - | - |
Other current assets | 5690.30M | 2954.10M | 2530.60M | 2871.50M | 2538.90M |
Total liab | 53142.60M | 38714.40M | 39651.20M | 40807.90M | 36587.00M |
Total stockholder equity | 10771.90M | 10649.80M | 8979.20M | 5641.60M | 2606.90M |